Mersana Therapeutics, Inc. - Common Stock, par value $0.0001 per share (MRSN)

Historical Holders from Q2 2017 to Q3 2025

Symbol
MRSN on Nasdaq
CUSIP
59045L106
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
4.99M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
55.4K
Holdings value
$411K
% of all portfolios
0%
Grand Portfolio weight change
0%
Number of holders
5
Number of sells
-78
Average Value change %
0%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Mersana Therapeutics, Inc. - Common Stock, par value $0.0001 per share (MRSN)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Nextech Crossover I GP S.a r.l. 10.4% $3.62M 12.1M Nextech Crossover I GP S.a. r.l. Dec 20, 2024
VANGUARD GROUP INC 6.72% $2.51M 8.38M The Vanguard Group Mar 31, 2025
BlackRock, Inc. 3% -52.9% $1.35M -$1.64M 3.76M -54.8% BlackRock, Inc. Jun 30, 2025
Venrock Healthcare Capital Partners III, L.P. 2.9% -67.5% $1.07M -$2.01M 3.57M -65.2% Venrock Healthcare Capital Partners III, L.P. Mar 31, 2025
Schonfeld Strategic Advisors LLC 5.48% +18.6% $2.12M -$41.9M 274K -95.2% Schonfeld Strategic Advisors LLC Sep 30, 2025

Institutional Holders of Mersana Therapeutics, Inc. - Common Stock, par value $0.0001 per share (MRSN)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 55.4K $411K -$31.5M $7.76 5
2025 Q2 77.2M $22.8M -$3.44M $0.30 80
2025 Q1 87.9M $30.3M -$35.8M $0.34 109
2024 Q4 104M $149M -$25M $1.43 129
2024 Q3 116M $219M +$3.27M $1.89 115
2024 Q2 114M $230M -$24M $2.01 121
2024 Q1 117M $526M +$29.1M $4.48 124
2023 Q4 46K $107K +$5.57K $2.32 1
2023 Q3 114M $144M -$76.7M $1.27 126
2023 Q2 112M $370M +$12.9M $3.29 145
2023 Q1 106M $436M +$19M $4.11 154
2022 Q4 101M $593M +$39.1M $5.86 149
2022 Q3 85.1M $575M +$49.8M $6.76 144
2022 Q2 87.8M $405M +$42M $4.62 118
2022 Q1 80.8M $322M +$33.2M $3.99 125
2021 Q4 60.5M $376M -$4.57M $6.22 113
2021 Q3 66.7M $629M -$40.9M $9.43 107
2021 Q2 70.5M $957M -$10.4M $13.58 128
2021 Q1 67.3M $1.09B -$33.3M $16.18 128
2020 Q4 65.7M $1.75B +$31.2M $26.61 143
2020 Q3 66.9M $1.25B +$47.7M $18.62 129
2020 Q2 63.9M $1.49B +$669M $23.40 127
2020 Q1 40.1M $234M +$26.4M $5.83 81
2019 Q4 35.5M $203M -$6.01M $5.73 68
2019 Q3 35.7M $56.3M -$6.86M $1.58 69
2019 Q2 37.6M $152M +$5.95M $4.05 75
2019 Q1 36.9M $194M +$105M $5.26 64
2018 Q4 16.4M $66.7M -$9.13M $4.08 45
2018 Q3 19.8M $198M +$71.4K $10.00 45
2018 Q2 19.1M $342M +$7.92M $17.86 51
2018 Q1 18.7M $295M +$23.7M $15.77 56
2017 Q4 16.4M $270M -$3.74M $16.43 45
2017 Q3 16.6M $288M +$10.6M $17.29 40
2017 Q2 17M $236M +$236M $13.97 29